关于接受关联方担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于接受关联方担保的情况概述 为满足日常经营和业务发展资金需要，朗姿股份有限公司（以下简称"公司" 或"朗姿股份"）向中国邮政储蓄银行股份有限公司北京顺义区支行（以下简称"邮 储银行"）申请流动资金借款人民币 1,500 万元，公司控股股东、实际控制人申东 日先生及其配偶翁洁女士为公司提供保证担保。 公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司提供本次保 证担保，该担保不向公司收取任何担保费用，也不需要公司提供反担保。 二、被担保人基本情况 朗姿股份 证券代码：002612 证券简称：朗姿股份 公告编号：2025-037 朗姿股份有限公司 法定代表人：申东日 注册资本：442,445,375 元人民币 成立日期：2006 年 11 月 09 日 注册地址：北京市顺义区马坡镇白马路 63 号 经营范围：一般项目：服装服饰零售；服饰研发；服饰制造；服装服饰批发； 服装、服饰检验、整理服务；服装辅料销售；互联网销售（除销售需要许可的商 品）；服装辅料制造；服装制造；针纺织品及原 ...

Group 1 - Aerospace Science and Technology expects a net profit of 68 million to 95 million yuan for the first half of 2025, representing a growth of 1628.83% to 2315.27% compared to the same period last year [1] - Huaxia Airlines anticipates a net profit of 220 million to 290 million yuan for the first half of 2025, an increase of 741.26% to 1008.93% year-on-year [1] - Shida Group forecasts a net loss of 44 million to 65 million yuan for the first half of 2025, marking a shift from profit to loss [1] Group 2 - Jiaao Environmental Protection expects a net loss of 70 million to 90 million yuan for the first half of 2025 [3] - Haima Automobile predicts a net loss of 60 million to 90 million yuan for the first half of 2025, compared to a loss of 152 million yuan in the same period last year [3] - Huaibei Mining anticipates a net profit of approximately 1.027 billion yuan for the first half of 2025, a decrease of about 65% year-on-year [3] Group 3 - Quanfu Automobile expects a net loss of 155 million to 185 million yuan for the first half of 2025 [5] - Gaode Infrared signed a procurement agreement worth 879 million yuan, which is expected to positively impact its operating performance for the year [5] - Zhongchen Co. won a project from Southern Power Grid worth 379 million yuan, representing 12.26% of its audited revenue for 2024 [5] Group 4 - Daheng Technology anticipates a net loss of 406,000 yuan for the first half of 2025, compared to a loss of 988,250 yuan in the same period last year [6] - Dazhongnan expects a net profit of 6.5 million to 8 million yuan for the first half of 2025, a recovery from a loss of 15.325 million yuan last year [6] - Xianfeng Holdings projects a net profit of 34 million to 42 million yuan for the first half of 2025, a year-on-year increase of 524.58% to 671.53% [7] Group 5 - Shuangxiang Co. expects a net profit of 115 million to 150 million yuan for the first half of 2025, a growth of 128.1% to 197.53% year-on-year [8] - ST Xintong anticipates a net loss of 67 million to 97 million yuan for the first half of 2025 [9] - Jishi Media forecasts a net loss of 187 million to 233 million yuan for the first half of 2025 [10] Group 6 - Suli Co. expects a net profit of 72 million to 86 million yuan for the first half of 2025, a year-on-year increase of 1008.39% to 1223.91% [11] - Wanli Co. anticipates a net loss of 19 million yuan for the first half of 2025, compared to a loss of 12.9238 million yuan last year [12] - Langzi Co. projects a net profit of 22 million to 26 million yuan for the first half of 2025, an increase of 31.74% to 55.69% year-on-year [14] Group 7 - Changjiang Securities expects a net profit of 1.652 billion to 1.81 billion yuan for the first half of 2025, a growth of 110% to 130% [15] - Huahong Technology anticipates a net profit of 70 million to 85 million yuan for the first half of 2025, a year-on-year increase of 3047.48% to 3721.94% [16] - Chenhua Co. plans to invest 30 million yuan in financial products with an expected annual yield of 3.20% [16] Group 8 - Zijing Mining expects a net profit of approximately 23.2 billion yuan for the first half of 2025, a growth of about 54% year-on-year [28] - Limin Co. anticipates a net profit of 26 million to 28 million yuan for the first half of 2025, a year-on-year increase of 719.25% to 782.27% [29] - Huazhong Securities expects a net profit of 1.035 billion yuan for the first half of 2025, a growth of 44.94% year-on-year [30]

追溯调整原因：同一控制下企业合并 2024 年 9 月，公司下属全资子公司北京朗姿医疗管理有限公司以现金方式 分别收购北京米兰柏羽丽都医疗美容医院有限公司（以下简称"北京丽都"）100% 股权和湖南雅美医疗美容医院有限公司（以下简称"湖南雅美"）70%的股权。本 次收购属于同一控制下企业合并，按照《企业会计准则》相关规定，需对 2024 年 6 月 30 日的合并资产负债表、2024 年 1-6 月的合并利润表及合并现金流量表相 关财务数据进行追溯调整，即公司将北京丽都、湖南雅美 2024 年 1 月至本报告 期末的经营成果和现金流量纳入合并财务报表。 （一）业绩预告期间 证券代码：002612 证券简称：朗姿股份 公告编号：2025-036 朗姿股份有限公司 2025年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 朗姿股份有限公司（以下简称"公司"）是否需追溯调整或重述以前年度会 计数据：是 二、与会计师事务所沟通情况 公司本次 2025 年半年度业绩预告相关财务数据未经会计师事务所预审计。 三、业绩变动原因说明 20 ...

行 业 及 产 业 美容护理 2025 年 07 月 13 日 行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 (8621)23297818× wanglp@swsresearch.com ⚫ 本周化妆品医美板块表现弱于市场。2025 年 7 月 4 日至 2025 年 7 月 11 日期间，申 万美容护理指数上涨 1.5%，表现弱于市场。其中，申万化妆品指数上涨 2.6%，强于申 万 A 指 1.1pct；申万个护用品指数基本持平，弱于申万 A 指数 1.6pct。 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 再生药械再添两员，轻医美概念方兴未艾 看好 ——化妆品医美行业周报 20250713 - 本期投资提示： ⚫ 周观点：再生药械再添两员，轻医美概念方兴未 ...

Group 1: Company Overview - Renqiao Asset recently conducted research on a listed company, Langzi Co., which showed varied performance among its medical beauty brands in Q1 2025, with Jingfu Medical Beauty's net profit increasing by 633.07% while other brands like Milan Baiyu and Wuhan Wuzhou experienced declines [1] - Langzi Co. aims to focus on technological innovation, customer needs, marketing channel optimization, and data governance in its medical beauty business, adhering to the philosophy of "safe medical beauty, reputation medical beauty, and quality medical beauty" without engaging in price competition [1] - The company has reduced its holdings in Ru Yuchen and accounted for the difference between the book value and the proceeds from the sale as investment income [1] Group 2: Financial Performance - In Q1, the revenue distribution among medical beauty departments was 45.14% for minimally invasive, 39.95% for dermatology, and 14.57% for surgery [1] - The sales expense ratio for medical beauty was 35.53%, with major marketing channels including local life platforms and short video platforms [1] - Online sales in the women's clothing segment increased by 14.31%, raising its revenue share to 42.62% of the women's clothing business [1]

Core Viewpoint - The hair medical concept sector has shown a positive performance with a 1.77% increase, ranking 7th among various concept sectors, driven by significant gains in stocks like Xiaofang Pharmaceutical, Baicheng Pharmaceutical, and Jiuzhitang [1] Group 1: Sector Performance - The hair medical concept sector experienced a 1.77% increase, with 17 stocks rising, including Xiaofang Pharmaceutical (up 6.65%), Baicheng Pharmaceutical (up 6.05%), and Jiuzhitang (up 6.00%) [1] - The sector attracted a net inflow of 114 million yuan from main funds, with Jiuzhitang leading the inflow at 74.56 million yuan [1] Group 2: Fund Inflow Ratios - Baicheng Pharmaceutical, Aoyang Health, and Yisheng Pharmaceutical had the highest net inflow ratios at 10.73%, 7.21%, and 6.37% respectively [2] - Jiuzhitang recorded a net inflow of 74.56 million yuan with a turnover rate of 27.18% [2] - Other notable stocks include Langzi Co. (up 5.16% with a net inflow of 20.14 million yuan) and Aoyang Health (up 1.03% with a net inflow of 10.81 million yuan) [2]

证券代码：002612 证券简称：朗姿股份 朗姿股份有限公司 投资者关系活动记录表 3、请介绍一下公司体外产业基金医美机构收购计划 回复：公司将在满足收购条件的前提下加速推进体外医美 机构纳入合并范围。体外机构收入体内的标准主要是规范性和 成长性。近年内，医美行业的成长性被诸多企业看好，收购市 场竞争较为激烈。为提前锁定有成长潜力的医美机构，公司通 过医美产业基金前期先筛选和孵化，主要基于以下考虑：一方 面，医美行业处于成长初期，市场上可供选择的成熟机构有限， 与公司相符合的商业模式尚未建立，经营能力尚不稳定，利润 较少或不确定，若用上市公司直接收购会导致公司营业利润的 大幅波动；另一方面，医美产业基金收购的大部分医美机构尚 处于早期的不规范阶段，不具备直接收入上市公司的条件，需 要进行一段时间的合规梳理和规范运营后才能进行体内收购。 同时，公司致力于医疗美容机构管理多年，已积累了一整套较 为科学和完善的客户引流、医疗诊治、业务流程和售后服务体 系，具备了可复制的医美机构管控模式。近年来，采用"体外 培育+ 成熟后收购"模式也已得到相关行业的上市公司的普遍 接受。截至目前，公司设立的七支医美并购基金共持有 7 ...

Core Insights - The light medical beauty market in China has surpassed half of the overall medical beauty market, becoming the mainstream beauty method by 2024, with significant contributions from non-invasive and minimally invasive procedures [1][2] Market Overview - Light medical beauty is defined as professional medical beauty projects that fall between surgical procedures and lifestyle beauty, utilizing non-invasive or minimally invasive methods for skin management, contour modification, and anti-aging effects [1] - The rapid growth of the light medical beauty market is attributed to its advantages such as minimal trauma, quick recovery, significant results, and relatively low risks, aligning with modern consumers' dual demands for beauty and quality of life [2] Consumer Trends - The penetration rate of the light medical beauty market is increasing, with 34% of consumers planning to engage in light medical beauty services in the coming year, marking a 36% increase from the previous year [4] - Among the interested consumer group, over one-third are new entrants, injecting fresh growth vitality into the Chinese medical beauty industry [4] Popular Products - Injectable and photothermal products are the main attractions for light medical beauty consumers, with ultrasound-based products (e.g., ultrasound scalpel) rapidly gaining popularity [5] Consumption Behavior - Consumers are increasingly rational in their light medical beauty choices, prioritizing needs-based combinations of projects and products, with over half selecting options based on specific needs [7] - The average planned consumption has increased to 2.4 projects per consumer, reflecting a 14% year-on-year growth [7] Consumer Demographics - The consumer base for light medical beauty exhibits high retention and strong growth, with seasoned consumers making up 35% of the existing market, indicating their essential role in the market [10] - Among the new consumer group, high-end novices represent 38%, characterized by high standards for beauty and a willingness to pay, with a focus on facial anti-aging solutions [10]

行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 行 业 及 产 业 美容护理 2025 年 07 月 06 日 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 (8621)23297818× wanglp@swsresearch.com 25H1 收官国货表现分化，毛戈平等领衔增长 看好 ——化妆品医美行业周报 20250706 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 - ⚫ 本周化妆品医美板块表现弱于市场。2025 年 6 月 27 日至 2025 年 7 月 4 日期间，申 万美容护理指数下滑 0.6%，表现弱于市场。其中，申万化妆品指数下滑 1.5%，弱于申 万 A 指 2.7pct；申万个护用品指数上涨 0.7%，弱于申万 A 指数 0.4pct。 ⚫ 周观点：25H1 收官国货表 ...

Market Performance - The hair medical concept sector rose by 2.34%, ranking 10th among concept sectors, with 19 stocks increasing in value, including JiuZhiTang which hit the daily limit, and TianEnKang, KangHui Pharmaceutical, and KangYuan Pharmaceutical which rose by 6.42%, 5.16%, and 4.55% respectively [1] - The top gainers in today's market include the fruit index at 4.73%, PCB concept at 3.27%, and AI mobile at 2.92%, while the military restructuring concept saw a decline of 1.49% [1] Capital Flow - The hair medical concept sector experienced a net inflow of 219 million yuan, with 11 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 10 million yuan. JiuZhiTang led with a net inflow of 172 million yuan, followed by ShuiYang Co., KangYuan Pharmaceutical, and NengTe Technology with net inflows of 34.25 million yuan, 21.05 million yuan, and 13.44 million yuan respectively [1] - In terms of capital inflow ratios, JiuZhiTang, ShuiYang Co., and KangHui Pharmaceutical had the highest net inflow rates at 33.17%, 6.81%, and 6.15% respectively [2] Stock Performance - JiuZhiTang saw a significant increase of 10.06% with a turnover rate of 7.62%, while ShuiYang Co. and KangYuan Pharmaceutical increased by 3.12% and 4.55% respectively [2] - Stocks such as *ST JinBi and AoYang Health experienced declines of 0.69% and 0.26% respectively, indicating some volatility within the sector [1][3]